NRx Pharmaceuticals, Inc.
Support and Resistance Levels
Past performance
News About NRXP
All events for NRXP
All deals for NRXP
Financial Ratios
Financial Statements
NRXP vs Sector & Peers
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware. Website nrxpharma.com
Headquarters Wilmington, DE, US